News - 13 Mar `24Lessons In Marketing: How To Sell A Disease To Big Pharma

New

Seeing Incyte’s “See What’s Possible” campaign — complete with larger-than-life vitiligo models at the AAD meeting in San Diego — was a milestone for our community.

For years, vitiligo flew below the healthcare industry’s radar. Today, it’s front-and-center: the first FDA-approved therapy is on the market, and more than 40 companies are investing in vitiligo R&D.

That momentum didn’t appear by chance; it grew from steady advocacy, data-driven storytelling, and a lot of patient and caregiver voices refusing to be invisible.

It’s proof that even a small non-profit like VRF can help shift perceptions and priorities across an entire field. We’re even considering a white paper on the journey, with the working title “How to Bring an Overlooked Disease to Pharma’s Attention.”

If you’d like to contribute insights or client-side perspectives, let us know!

— Yan Valle

CEO, Vitiligo Research Foundation | Author, A No-Nonsense Guide to Vitiligo

Vitiligo marketing

AAD, 2024

AAD, 2025

 



      FAQOther Questions

      • I have vitiligo: will my children have vitiligo, too?

        If you have vitiligo, you might wonder about the chances of your children developing the condition. While there is a genetic component, vitiligo is not a straightforward heredit...

      • Shall I try low-fat diet for my vitiligo?

        The link between dietary fat and autoimmune diseases like vitiligo is a compelling yet complex puzzle that continues to intrigue scientists. While the conversation is ongoing, o...

      • Vitiligo and Pregnancy

        Pregnancy with vitiligo? The good news: vitiligo itself doesn’t make pregnancy unsafe. Most women stay stable (some even improve), though flares can pop up after birth — usually...